In this episode, John Flavin sits down with Dr. Ivan Liachko, co-founder and CEO of Phase Genomics, a company at the forefront of genomics and microbiome research. Ivan shares his journey from a young immigrant fascinated by biology in Ukraine to a biotech leader based in Seattle. His academic path began with a keen interest in genetics, leading him to work at the University of Washington, where he honed skills in both genetics and computer science. Dr. Liachko discusses how Phase Genomics emerged from a passion project to solve unique biological challenges, evolving into a full-fledged company offering genome assembly services, microbiome diagnostics, and groundbreaking cancer diagnostic tools. Ivan’s focus on innovation is clear, as he reflects on the importance of courage, community, and resilience when transforming science into industry. As the conversation unfolds, Ivan delves into his vision for future scientific breakthroughs and the value of an ecosystem that supports unconventional thinking. 

In this insightful episode of Lab Rats to Unicorns, Steve Lehmann sits down with Dr. Zhenpeng Qin, Associate Professor of Mechanical and Bioengineering at the University of Texas at Dallas. Dr. Qin shares his groundbreaking work in biomedical engineering, focusing on the development of nanomaterials to advance diagnostics and therapeutic delivery. From innovations in nanoparticle technology to exploring the blood-brain barrier for treatment delivery, Dr. Qin’s journey reveals the power of interdisciplinary research. This episode dives into the evolution of his career, his shift from traditional mechanical engineering to medical applications, and his vision for the future of biomedical technology.

Join us for a conversation with Dr. Raghu Kalluri, a leading figure in cancer biology, who serves as the Chair of the Department of Cancer Biology at MD Anderson Cancer Center. With over 300 publications, multiple successful biotech ventures, and groundbreaking work in exosome research, Dr. Kalluri discusses the intricate relationship between science, medicine, and industry, his career path from researcher to entrepreneur, and his exciting vision for using innovation to transform cancer care. 

Join us on Lab Rats to Unicorns as we dive into the career of Michael Torres, CEO of Crossbridge Bio. With a Ph.D. in cancer biology and a background in equity research, Michael has been at the forefront of developing cutting-edge oncology treatments. In this episode, he discusses the evolution of antibody-drug conjugates (ADCs) and the process of building biotech companies in the Texas innovation ecosystem, as well as his personal journey from researcher to CEO. 

Join us on Lab Rats to Unicorns as we dive into the inspiring journey of Dr. Jochen Reiser, President of UTMB and CEO of UTMB Health System. A nephrologist, healthcare executive, and biotech entrepreneur, Jochen shares insights from his transition into the U.S. medical landscape, his pioneering research in kidney disease, and the founding of Walden Biosciences. This episode explores the exciting intersection of clinical care, research, and innovation. Key Topics:Jochen’s transition from Germany to the U.S. and his research in nephrology Founding and commercializing Walden Biosciences for kidney disease Leading UTMB as President and fostering innovation Balancing clinical care, research, and education in healthcare Collaboration and team-building in the biotechnology sector 

Join Steve Lehmann & Jeremy Langsam from Portal's Stargaze team on a bimonthly segment of Lab Rats to Unicorns: Rising Stars. In this episode, they explore the groundbreaking work of Zachi Attia, the Director of Artificial Intelligence at Mayo Clinic. With a rich background in electrical engineering and a Ph.D. in Bioinformatics, Zachi discusses his pivotal role in advancing AI models that predict and screen cardiovascular diseases. From his innovative research to real-world applications that are saving lives, this episode offers an inspiring look into the future of healthcare. 

In this captivating episode of Lab Rats to Unicorns, we journey into the universe of biotechnology with Steve Lehmann, Director of Venture Operations, and Jeremy Langsam, Venture Analyst at Portal Innovations.In this episode, Steve and Jeremy share their insights into the relay race of innovation—from the "aha" moments in the lab to creating groundbreaking companies with global impact. They delve into the evolution of innovation ecosystems and how tools like Stargaze allow us to plant the seeds for future growth by identifying emerging clusters and talents.Through vivid metaphors and real-world examples, Steve and Jeremy illuminate the complex process of turning cutting-edge science into lifesaving treatments and products. Whether you're an aspiring entrepreneur, a seasoned scientist, or simply curious about the future of biotech, this episode is packed with inspiration and wisdom from those at the forefront of scientific discovery.

In this episode, Dr. Walter E. Massey shares insights from his illustrious career in science and academia, detailing his journey, evolving focus, and key advancements in physics that have shaped his work. He discusses significant leadership decision points, his approach to decision-making, and offers guidance on preparing for impactful choices. Reflecting on his tenure at the National Science Foundation, Dr. Massey highlights the crucial role of government in scientific research and policy. He explores the enriching intersection of disciplines, particularly between art and science, emphasizing how such fusions drive innovation. Personal inspirations, including influential mentors, books, and events, are shared to illustrate his life philosophy and career decisions. Dr. Massey also delves into the cultural and community aspects of science, discussing the responsibilities of educators and leaders in shaping the future of scientific innovation for greater social impact. 

Episode 54 of LRTU wants us to know about Tony Martignetti, the founder and chief inspiration officer at Inspired Purpose! With over 25 years of experience in the life sciences and tech sectors, Tony brings a wealth of knowledge and a unique perspective on leadership. He shares his journey from being a pre-med major to holding pivotal roles in biopharma companies like Genzyme and Sarepta, before transitioning to a career in leadership coaching. Throughout the episode, Tony emphasizes the importance of curiosity, compassionate leadership, and creating environments that foster innovation and connection. His grounded leadership framework, centered on the three C's—connection, curiosity, and compassion—offers valuable insights for leaders at all levels.Tony also discusses his bestselling books, "Climbing the Right Mountain" and "Campfire Lessons for Leaders," where he delves into finding fulfillment in the journey rather than the destination. He highlights the significance of embracing a beginner's mind, encouraging leaders to ask questions and remain open to new ideas. Through meaningful anecdotes and practical advice, Tony illustrates how leaders can unlock their true potential and inspire their teams. Join us for an inspiring conversation that explores the transformative power of curiosity and the impact of compassionate leadership in driving innovation and success.

Join us on episode 53 of Lab Rats to Unicorns as we sit down with Solomon Wilcots, a former NFL player who has transitioned into a health advocate. Solomon invites us on his remarkable journey from the competitive arenas of professional sports into the insightful world of broadcast television, and further into the impactful realm of health communications. He discusses the vital roles of teamwork and community, principles ingrained during his sports career, which now fuel his mission to advance medical science and patient care, with a particular focus on brain health and Alzheimer's research. Tune in to discover how Solomon utilizes his extensive platform to drive global change and why he believes continuous learning is essential for making a significant impact.Throughout his diverse career, Solomon has been a prominent figure across broadcast television and radio, notably as a game analyst for CBS Sports and a contributor to the NFL Network. His broad experience includes roles as a studio analyst and sideline reporter, covering major events such as multiple Super Bowls and NCAA basketball tournaments. Shifting focus from sports, Solomon now plays a crucial role in health communications as the leader of the Sports-Health Division at Russo Partners LLC. In this capacity, he spearheads initiatives like "Huddle Up for New Alzheimer's Treatments," which has dramatically increased enrollment in clinical trials. His efforts also involve creating content that links biotech innovations with a wider audience, further illustrating his profound impact across both the sports and health sectors.

In this episode of "Lab Rats to Unicorns," recorded at TMC's Helix Park in Houston during a Portal Pours event, we're joined by a distinguished panel led by featured host Ritu Shah, a seasoned expert in the biopharma industry and Managing Director at Portal Innovations. The conversation features: Sarah Hein, the visionary founding CEO of March Biosciences, a trailblazer in clinical-stage cell-therapy, with a rich background in cancer therapeutics and antibody therapeutics platform technologies. Rahul Aras, a dedicated executive with a robust 15+ years in the pharma/biotech sector, currently leading the charge in early-stage technology advancement and business development, recognized for his role at Iterion Therapeutics. Michael Torres, an entrepreneur with a fervent mission to turn science into medicine, leveraging his experience in biotech company formation and equity research to make significant strides at Crossbridge Biotech. Together, they delve into the dynamics of Houston's biotech ecosystem, sharing their unique perspectives on innovation, the challenges of startup culture, and the path forward in transforming patient care. 

In this live taping of Lab Rats to Unicorns, John Flavin and Jeff Karp discuss the challenges and triumphs of bringing lab research to market, the evolving landscape of biotech startups, and the importance of interdisciplinary collaboration in driving scientific breakthroughs. Dr. Jeff Karp is a renowned figure in the biotechnology sector, known for his groundbreaking work and innovative approaches in the field. With a career that bridges both academic research and industry application, Dr. Karp has been at the forefront of developing cutting-edge biotechnological solutions to some of healthcare's most pressing challenges. Jeff is the Distinguished Chair at Brigham and Women's Hospital, a Professor at Harvard Medical School, Affiliate Faculty at MIT & The Broad Institute, and Principal Faculty at the Harvard Stem Cell Institute His expertise spans a range of areas, including drug delivery systems, regenerative medicine, and tissue engineering. Dr. Karp's work is characterized by a commitment to translational research, aiming to bring laboratory discoveries into practical medical use. His leadership in various biotech initiatives and collaborations has been instrumental in driving forward the boundaries of medical science and patient care. Jeff has won numerous awards around his innovations and entrepreneurial successes. 

In this episode of "Lab Rats to Unicorns," we're thrilled to spotlight Ritu Shah, the Managing Director at Portal Innovations, whose distinguished career in the biopharma industry spans over two decades. Ritu's unparalleled expertise shines in her role, where she's instrumental in driving growth and enhancing the value of portfolio companies. Specializing in steering early-stage companies towards key milestones and securing funding rounds, her strategic prowess has been key to numerous mergers & acquisitions, company formations, and operations.    Ritu Shah's journey includes significant roles as a fractional executive, showcasing her versatility through part-time contracted positions as a senior executive with Dimension Inx., head of operations and senior advisor with Reax Biotechnologies, and CEO of ClostraBio. At Portal, she spearheaded the innovative Ex^3 fractional C-suite model for life science clients, marking a significant milestone in her illustrious career. Join us as we explore the intricate dynamics of biotech's fast-evolving landscape, illuminated by Ritu Shah's remarkable insights and achievements. 

In this episode, we venture into the intricate world of life science innovation spaces with James Lewis and Mason Ailstock. From the nuances of creating standout spaces that cater to diverse innovator types to the importance of location in driving differentiation, we dissect what truly makes an innovation hub thrive. As we spotlight their landmark projects, James and Mason share insights into pivotal decision points that have shaped their work. Beyond the structures and spaces, we also delve into the Atlanta market's present dynamics and its prospective horizon. Through it all, the personal journeys of our guests enrich our understanding, merging the professional with the personal in a tale of ambition and accomplishment. 

We're thrilled to welcome Kenneth T. Christensen, Provost and Senior Vice President for Academic Affairs at Illinois Institute of Technology to this episode of LRTU! With a career spanning decades at the forefront of engineering and academia, Christensen brings a wealth of knowledge and insight. In this episode, we'll explore the intersection of academia and industry, the evolving landscape of engineering education, and the role of research in addressing some of today's most pressing environmental challenges. Christensen shares his journey from a mechanical engineering student to a leader in academic administration, shedding light on the path to academic leadership and the importance of industry partnerships in fostering innovation and economic development. 

Erika Jefferson stands at the intersection of leadership, innovation, and advocacy in the STEM world. She is the President and Founder of Black Women in Science and Engineering (BWISE), an initiative born out of the need to bridge the leadership gap for Black women in STEM fields. Erika's academic foundation, with a BS in Chemical Engineering from LSU and an MBA from Georgia Tech, set the stage for a career that spanned various roles and cities. Having worked at industry-leading companies like Amoco, BP, Chevron, and Praxair, Erika's roles have ranged from sales and business development to supply chain and operational functions. Her professional journey, taking her to locales from Chicago to Houston, echoes her adaptability and breadth of experience. Through BWISE, Erika channels her insights and experiences to support and uplift Black women in STEM, addressing both the challenges they face and the opportunities that lie ahead. 

On this episode of "Lab Rats to Unicorns," we sit down with Julie Gilmore, Ph.D., Lilly’s vanguard in bridging the worlds of big pharma, startups, and academia. With over two decades at Lilly, Julie unpacks the role big pharma plays in scientific innovation and the multifaceted career paths and opportunities within it. We'll delve into her experiences in portfolio management, explore the nuances of life science communications, and dissect Lilly’s synergistic relationship with burgeoning startups and universities. Julie also shares her personal narrative of growth and leadership, her mentoring philosophies, and her acumen in spotting potential in the startup arena. Join us for a deep dive into the ecosystem of pharmaceuticals and the minds shaping its future. Julie Gilmore, Ph.D., is the Vice President and Global Head for Gateway Labs by Lilly, where she has cultivated a distinguished 20-plus-year tenure. Her journey with Lilly has seen her ascend through various leadership and scientific roles, demonstrating her versatility and expertise across research and drug development. Notable positions include her tenure as Head of Information Sciences and Clinical Operations for Lilly Europe, Global Head of Scientific Communications, and Global Head of Portfolio Management for the Neurodegeneration and Pain Early Phase Portfolio. Julie's influence extends beyond her corporate achievements; she serves on the Board of Governors for Biocom California and the Board of Directors for Mozart Therapeutics and DTx Pharma. A mentor at heart, Julie dedicates herself to guiding the next generation of scientific leaders through her involvement in several university graduate programs. Her academic credentials are equally impressive, with a doctorate in Membrane Biophysics from Purdue University and a postdoctoral fellowship in Drug Transport from Indiana University School of Medicine. 

This episode features a conversation in front of a live audience in Atlanta with Dr. James Lillard. Dr. Lillard is a Distinguished Fellow of AAI and Fellow of NAI and AAAS that uses both in silico and in vivo methods to develop biologics or molecular tests to better treat or diagnose, respectively, chronic diseases. His research involves dissecting the molecular mechanisms of cancer and inflammatory diseases, using clinically annotated NGS data and the implementation of precision medicine. His research contributions span disciplines including oncology, immunity, inflammation and biodefense. Dr. Lillard’s cumulative peer-reviewed funding principally directed over his scientific career exceeds $75 million and he has authored over 300 scientific communications, which have been cited over 10,000 times.

Dr. Todd Sherer has dedicated over three decades to the advancement of academic technology transfer, ensuring research, especially federally-funded, translates into life-saving applications for the public. As the helm of Emory’s Office of Technology Transfer since 2003, he transformed the department into a global leader in the field. Instrumentally, he innovatively introduced product pipelines to highlight research's role in innovation, streamlined partnerships with industries, and orchestrated the strategic monetization of Emory’s HIV drug royalties for Emtriva, securing an unprecedented $540 million. His vast experience, which spans roles at Oregon Health & Science University, the University of Oregon, and Washington State University, is complemented by his contributions to the broader technology transfer community, notably as a Past President of the Association of University Technology Managers (AUTM).

e.043!! Learn about & from: Lesley Millar-Nicholson! Ms. Millar-Nicholson is the Executive Director of the Massachusetts Institute of Technology, Technology Licensing Office (TLO) and was part of the founding leadership team of the recently formed MIT Office of Strategic Alliances and Technology Transfer (OSATT). As TLO Executive Director, she leads a team managing MIT’s intellectual assets and technology transfer process. Prior to arriving in Cambridge Ms. Millar-Nicholson was Director of the Office of Technology Management (OTM) at the University of Illinois, Urbana/Champaign, managing the technology transfer and commercialization processes for over 10 years.Ms. Millar-Nicholson is a Past President of the Board of Governors of Certified Licensing Professionals Inc, (CLP Inc.), a former member of the Board of Directors of the Licensing Executive Society (LES), and is on the Board of Cambridge Enterprise, UK as an external advisor. A native of Scotland, Ms. Millar-Nicholson has a B.Ed., M.Ed., and MBA and is a Certified Licensing Professional (CLP). 

Ryan Meyers is a skilled biotech executive with significant experience in management consulting, venture capital and company creation. He is the co-founder of both AddGraft Therapeutics – a novel skin based cell therapy platform – as well as Alnair Therapeutics - which aims to develop a platform technology that improves the delivery of drugs to difficult-to-treat cancers. Ryan has his MBA from the Booth School of Business at the University of Chicago, and in his early career he worked a places like Gibson Consulting and AArete Consulting. In this episode, Ryan breaks down different opportunities for startups, important milestones in company creation, describes the unique challenges (as well as ways to overcome them) and the responsibilities of leaders in the life sciences. He brings up his learning process and the interaction of business and science - how a hopeful future has an important focus on accessibility.

e.041 is another live audience recording! Taped in partnership with Marcus Whitney and his awesome podcast Health: Further, this one takes a unique form. Jump into a wide conversation from the macroeconomic environment entrepreneurs are facing currently to broadening the health equity conversation. The conversation explores the perspectives of Kedar Mate (Institute for Healthcare Improvement), Kameron Matthews (CityBlock Health), Anna Haghgooie (Valtruis) and Michael Gray (Neal, Gerber & Eisenberg).

e.040: David Steinberg is a General Partner at Longwood Fund. He is currently Chairman of the Board of Longwood portfolio companies Photys Therapeutics and Be Biopharma, where he also served as founding Chief Executive Officer, and serves on the board of Longwood portfolio companies AAVantgarde Bio, Carbon Biosciences, Lassen Therapeutics, and Rectify Pharmaceuticals.Previously, he was co-founder and Chief Innovation Officer of biotech venture creation firm PureTech Health (NASDAQ: PRTC), focusing on launching and investing in innovative biotech companies. David was the co-founder and CEO of several biotech companies, including Longwood-founded companies Pyxis Oncology (NASDAQ:PYXS) , Photys Therapeutics, Be Biopharma, and Carbon Biosciences as well as co-founder and CEO of Vor Biopharma (NASDAQ: VOR), Vedanta Biosciences, and Calix, and co-founder of Restorbio (NASDAQ:TORC). He previously worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and R&D at P&G Pharmaceuticals. David received his MBA in strategy and finance from the University of Chicago Booth School of Business and holds a BA in biology from Cornell University.

e.039 was recorded in front of a whole audience of ppl in dorchester because that seemed like a pretty fun idea. in this episode, Rahul Dhanda (founder, ceo & prez of Syntis Bio) gives us the story of his career; teaches us a few lessons on #biotech research, startup creation & culture development; and he breaks DOWN the trap and residual harm of siloes in innovation. Rahul Dhanda is co-founder, CEO and director of Syntis Bio - a team we love and cherish. previously, Rahul co-founded Sherlock Biosciences, where he was CEO, president and director, and built a diverse team that launched the first CRISPR product authorized by the FDA. an advocate of equity in society and STEM, Rahul founded The 221b Foundation, a non-profit providing CRISPR intellectual property in exchange for profit sharing to promote gender and racial equity in STEM. named to boston’s Power50 list by the Boston Business Journal, Rahul also led Sherlock to recognition as a Fast Company Most Innovative Company, a Red Herring Top 100 Company, Fierce15 MedTech, Tech Pioneer by the World Economic Forum, and Top 50 Innovative Company by BostonInno. not everyone gets named to even one list in their life...so thts pretty wild.Rahul holds an MBA from MIT’s Sloan School of Management, a B.A. from Wesleyan University, and authored the first book addressing the crossroads between industry and bioethics, entitled Guiding Icarus: Merging Bioethics with Corporate Interests. ok thts all u should need, now get outta here...go listen !!

James Dahlman is a biomedical engineer who works at the intersection of nanotechnology, molecular biology, and genomics. He is an associate professor at Georgia Institute of Technology and Emory School of Medicine, and the director of the Lab for Precision Therapies. His lab designs drug delivery vehicles that target RNA and other nucleic acids to cells in the body, and uses DNA barcodes to screen thousands of nanoparticles in vivo. He has applied his technology to treat diseases such as heart disease, cancer, inflammation, and pulmonary hypertension. He has also developed new tools for gene editing using CRISPR-Cas9. James has received numerous awards for his research, including the McCamish Foundation Early Career Professorship. His work has been translated via Guide Therapeutics, which was spun out of Georgia Tech and acquired by Beam Therapeutics. He is also a passionate educator and mentor who loves to share his enthusiasm for science with students and the public.

Erandi De Silva is a biotech founder and scientist who co-founded Forge Biologics, a gene therapy development and manufacturing company headquartered in Columbus, Ohio. She serves as the Senior Vice President of Product Development, overseeing the pipeline of disease-modifying AAV-based therapies for rare genetic diseases, automation initiatives and new therapeutic product planning. She has over 15 years of experience in discovery research, therapeutic development, and partnering. She holds a Ph.D. in Molecular Biology from Princeton University and a B.S. (Honors) in Biological Sciences from Stanford University. She has a strong commitment and track record in building and managing diverse and innovative workforce

phew, huh, pssh, hmm….hard to maintain a cool composure for this week’s guest…dr. omar farha is an ESTEEMED scientist with an unwavering passion for advancing the field of chemistry and fostering innovation. he completed those undergrad studies at fullerton college before pursuing his PHD at UCLA, where he specialized in inorganic chemistry. dr. farha's remarkable career at northwestern university has seen him rise to the rank of professor of chemistry, making groundbreaking contributions in the realm of metal-organic frameworks and porous materials. alongside his academic TRIUMPHS, Dr. Farha is the co-founder and chief science officer at NuMat technologies, where his expertise plays a pivotal role in driving cutting-edge research. moreover & over, he is an advisory board member for several prestigious journals and institutions, including the journal of the american chemical society (shooot). in today's discussion, i’d say we are preettyy fortunate to delve into dr. farha's inspiring journey and the profound impact of his impressive accomplishments.

y’all… even we aren’t ready for this superstar… Dr. Courtney Law is a career scientist with remarkable achievements that exemplify her dedication to impacting human health. Law received her B.S. in Chemistry & Ph.D. in Pharmaceutical Sciences and Medicinal Chemistry & Natural Products from the University of North Carolina at Chapel Hill. after completing her postdoctoral fellowship at North Carolina Central University, she worked as a Tech Transfer intern at North Carolina State University. currently, Dr. Law leads Biolocity, where she “help[s] all Emory University and Georgia Institute of Technology faculty develop new biomedical innovations with commercial potential.” we are humbled and honored to be able to discuss Dr. Law’s current work at Biolocity and her passion for human health in this episode!We appreciate & cherish Suna Lumeh for cohosting this interview. She is deeply connected to Atlanta's life science ecosystem and is a driver of growth. Learn more about her here: https://www.portalinnovations.com/team-page/

We had the great privilege of being joined by two exceptional guests from Northwestern University for this live episode! And to make it even better, Kevin O’Connor joined the conversation as a co-host! First, let us introduce Dr. Richard B. Silverman, an esteemed medicinal chemist and dedicated educator, who holds the title of Patrick G. Ryan/Aon Professor of Chemistry. Dr. Silverman's research focuses on the design and development of pharmaceuticals, and he is notably the creator of the blockbuster drug pregabalin, sold under the brand name Lyrica. He is also the founder of Akava Therapeutics, Inc. –– a company committed to bringing innovative treatments to patients.Our second guest is the trailblazing neuroscientist, Dr. Hande Ozdinler, an Associate Professor of Neurology at Northwestern University. Dr. Ozdinler is dedicated to unraveling the mysteries of neurodegenerative diseases, with her research centered on understanding the cellular and molecular mechanisms underlying motor neuron diseases such as ALS. She is also a passionate advocate for raising awareness and funds for ALS research.In this episode, we're thrilled to explore the inspiring journeys, tireless efforts, and profound impact of both Dr. Silverman and Dr. Ozdinler in their respective fields. We will be particularly looking at Akava Therapeutics, diving into Dr. Silverman’s inspiration behind it, and learning what it takes for an idea to change lives. 

okie okie we can’t contain our excitement fr!!! maria thacker goethe is equally deeply committed to her important non-profit work & the development of biotechnology ecosystems!!! thacker goethe received her B.A from Sweet Briar College before attending Tulane School of Public Health & Tropical Medicine where she studied health marketing/communications & maternal & child health. thacker goethe’s dedication is notable; she has worked at georgia bio for almost seventeen years,,, climbing the ranks from marketing, project, & membership manager to president & ceo. additionally, she is a board member of the CJD Foundation & the American Red Cross of Georgia. we are like,,, truly!!! really!!! so lucky to discuss her experience in non-profit & impressive accolades in this episode!!! Wahoo!We appreciate & cherish Suna Lumeh for cohosting this interview. She is deeply connected to Atlanta's life science ecosystem and is a driver of growth. Learn more about her here: https://www.portalinnovations.com/team-page/

lol like how are some people just... able 2 do everything... like omg... Kyyah Abdul is a multi-talented and deeply passionate leader in public health who has not gone unnoticed!!! Abdul received her Bachelor's from the University of New Haven in Biology concentrated in Pre-Medical Studies and her Master's in Public Health from Charles R. Drew University concentrated in urban healthcare disparities. abdul has had a lengthy and notable career in regulatory aairs,,, working at institutions and organizations such as Yale University, Genentech/Roche, Pfizer, Amgen and Bristol Meyer Squibb (omg??). She founded (yeah. that too) Career Savage,,, a platform providing college students with career advice. Abdul recently released her book, The Prepared Graduate, dedicated to "helping students and young professionals navigate their road to ultimate career success." (tysm) it is truly truly such an honor to discuss how she has balanced her career with her other accolades !!

we’re honestly taken aback by this one… truly in awe… Nakia Melecio is truly a leader, uniquely juxtaposing his skills to help researchers commercialize in the sciences. Melecio received his B.A in Cognitive Science & a Master’s in education/teaching, learning & educational technology from Ashford University before receiving his Ph.D. from The University of Arizona Global Campus. Melecio is currently a senior research faculty member at Georgia Institute of Technology, an adjunct faculty professor at Morehouse School of Medicine, energy I-Corps instructor, & more. he volunteers as an inclusive tech entrepreneurship program (ITEP) mentor at Georgia Tech, ad-hoc proposal reviewer at the National Science Foundation, & mentor defense innovation accelerator at National Security Innovation Network. he has swathes of experience that we are so lucky to be able to delve into during this episode!!! We appreciate & cherish Suna Lumeh for cohosting this interview. She is deeply connected to Atlanta's life science ecosystem and is a driver of growth. Learn more about her here: https://www.portalinnovations.com/team-page/

Evonne Sepsis dedicates herself to the continued growth of the life sciences ecosystem. Sepsis received her undergraduate degree from Northwestern University and her MBA from the Yale School of Management. She started her career in investment banking at Salomon Brothers, was then the head of investment banking at Susquehanna Financial Group, and was Managing Director at C.E. Unterberg, Towbin. In 2008, Sepsis founded ESC Advisors, a boutique advisory firm focused on emerging companies in the life sciences ecosystem. Sepsis has had such a notable career, and we are excited to talk to her about how she did it and who she is!

okay… like… this is really really BIG!!! Dr. Dennis Liotta is the physical manifestation of true diligence, dedication, & commitment. Liotta obtained his Ph.D. in organic chemistry from the City University of New York in 1974. following this, he dedicated himself to drug discovery & is recognized as “one of the premier discoverers of novel therapeutics in the United States.” he is noted as authoring over 300 peer-reviewed articles, holds the inventorship to over 100 patents, his innovations have created at least 18 life-saving FDA treatments, & has co-founded more than 10 pharmaceutical companies. notably, Liotta’s research has been truly innovative in furthering HIV/AIDS research; Emory University Office of Technology Transfer estimates that 95% of people living with HIV/AIDS have taken a drug co-invented by Dr. Liotta!!! woah.. like really… woah… we are truly so lucky to be able to discuss his research & dedicated experience in drug discovery on this episode!!!We appreciate & cherish Suna Lumeh for cohosting this interview. She is deeply connected to Atlanta's life science ecosystem and is a driver of growth. Learn more about her here: https://www.portalinnovations.com/team-page/

whew… this one is… just. wow. D. Gayathri Srinivasan’s career and research accomplishments are truly remarkable. Srinivasan received her Ph.D. from The Ohio State University in Microbiology. She then headed to the Massachusetts Institute of Technology to serve as a postdoctoral fellow before serving as a Technology Licensing Associate there. she served as an Executive Board Member of M2D2 at the University of Massachusetts at Lowell. she currently serves as Managing Executive Director at the Office of Corporate and Foundation Relations at Emory University. joining us also on this episode is edie Stringfellow!!! edie Stringfellow is truly vehemently committed to developing ecosystems and it shows. Stringfellow received her Bachelor’s in communications & business management from Illinois State University before attending Boston College and receiving her Master’s in international relations and affairs. her professional career is more than impressive; she’s served as Practice Development Manager for Nutter, as Senior Business Development Consultant at The Dolan Company, and as Senior Director of Diversity, Equity, and Inclusion at MassBio. she now serves as Vice President of Ecosystem Development at the Center for Global Health Innovation. we r so impressed we dk what to do, but we are so excited to speak with them both and discuss their achievements!!!

Victor Pascucci III is a cofounder and Managing General Partner at Energy Capital Ventures and is a passionately devoted career venture capitalist and strategic investor. He received his BA in Communications from Bowling Green State University and his law degree from the University of Toledo. Pascucci has extensive career experience, ranging from vast board membership and advising experience to an almost decade-long career at USAA Financial Services. And before starting ECV, he was the Managing Director at Lightbank, a Chicago based tech venture fund founded by Eric Lefkofsky and Brad Keywell. Vic and I are good friends and I am eager to share his story with our listeners. Vic, welcome to the podcast!

Dr. Carnahan received his BS in Biology and BS in Psychology from Indiana University, jumped into the industry, working for Eli Lilly in both the US and France, then he came back to academia as a researcher at the Institut Pasteur in Paris, France. He completed his Ph.D. in Cell Biology at Vanderbilt University and his post-doc in the laboratory of Al Reynolds, Ph.D. In 2006, he was appointed as Director of the Vanderbilt Antibody and Protein Resource (VAPR). In addition to directing the VAPR, Dr. Carnahan is an Associate Professor in the Cancer Biology, Faculty director of the Management and Entrepreneurship for Scientists program, a member of the Medical School admissions IAC committee, and is a faculty instructor for both M.D. and Ph.D. training programs.  In 2010 he co-founded the Antibody-Technologies Research Group.

dr. meesha dogan's commitment to entrepreneurship is genuinely, like actually unparalleled & laudable!!! dogan received both a joint bachelor's and master's in chemical engineering and a Ph.D. in biomedical engineering from the University of Iowa. upon leaving Iowa in 2017,,, Dogan co-founded Cardio Diagnostics, where she now acts as CEO and co-founder. in 2021,,, FLIK named her one of their Womxn Entrepreneurs to Watch. Dogan shares with us the importance of preventative care, where the idea for her company came from, & more in this super fun episode!!!

okay… this one is honestly,,, soso exciting… like,,, dr. shana kelley is a highly driven and passionate scientist and intellectual!!! kelley received her B.S from Seton Hall University and promptly pursued her graduate and doctoral studies at the California Insitute of Technology!!! kelley's work in academia is outstanding and noteworthy; she has been a professor at the University of Toronto for sixteen years and is the Neena B. Schwartz Professor of Chemistry and Biomedical Engineering at Northwestern University. additionally, she is a founder of two companies, Arma Biosciences and CTRL Therapeutics, and sits on the board of numerous biotechnology companies. (wow!!!) in this episode,,, we are honored to listen to Kelley discuss her companies,,, her new position at Northwestern, the life sciences ecosystem, and sm more!!!

this is a super fun one!!! this week’s episode features Dr. Jim Audia,,, a deeply intelligent & passionate scientist! after receiving his bachelor’s & Ph.D in chemistry from the University of South Carolina, Audia did his postdoc at Yale University!!! he has flourished throughout his decades-long professional career, notably working at Eli Lilly & Constellation Pharmaceuticals for ten years each. audia also consults for a number of biotech companies,,, such as Ribon Therapeutics & Karuna Therapeutics! he sits on numerous scientific & philanthropic boards & was the former executive director of the Chicago Biomedical Consortium!!! we are so excited to have Dr. Audia discuss his work in medicinal chemistry this week, a subject he has undoubtedly dedicated himself and his life to!

e.022: you’re in for,,, a treat! Swamy Vijayan is a creator at heart. he’s run three companies as founder & ceo,,, and has deep experience in bringing interdisciplinary technologies to the market. he received a Ph.D in physics from the University of Pennsylvania and immediately began his professional career working in optics, molecular biology, nanofabrication, and computation analysis at a slew of different genomic companies. eventually, he began managing research on novel sequencing technologies as nanobiology group leader at Illumina. his first company, Omniome, worked to simplify instrumentation around DNA sequencing. at his second, Plexium, he led the way in the rational design and discovery of monovalent protein degraders across a wide range of modalities. in this episode, Dr. Vijayan discusses his third & current venture – Zafrens, polymer science, dna sequencing, and more.

we are… like so so lucky to have the,,, wonderful & awe-inspiring dr. cathryn nagler on the show this week to learn more about her, her entrance into the world of biotech, & discuss her work at her academic start-up company ClostraBio, the microbiome, food allergies & more! dr. nagler graduated w/ honors from Barnard College at Columbia University. she earned her Ph.D from NYU Grossman School of Medicine and did a postdoctoral fellowship @ mit! wow!!! after, she was associate professor of pediatrics @ Harvard Medical School before she joined the University of Chicago in 2009!!! she currently holds both national and international leadership roles related to publication & teaching for a bunch of places, such as the American Association of Immunologists, the Society for Mucosal Immunology & the Federation of Clinical Immunology Societies! also,,, she was listed among Crain’s Chicago Business Tech Top 50 Women in 2018 and Notable Women in HealthCare in 2019 for her work at ClostraBio & was elected as a Distinguished Fellow of the American Association of Immunologists (AAI) in 2020.

e.020...omg...don't even get us STARTED! We are here to learn about Dr. Garry Cooper – the Co-founder and CEO of Rheaply, a Chicago-based tech company that enables Fortune 500 companies, government agencies, cities, and universities to enter the circular economy through reuse. He also serves on the boards of directors of P33 Chicago and 1871, and the investor team at LongJump Ventures, of which he is a founding partner. Previously, Dr. Cooper served on the faculty of Northwestern University and facilitated supply chain and performance improvement for enterprise businesses at Ernst & Young. As a result of his work, Dr. Cooper has received recognition on the Forbes Next 1000, Chicago magazine’s The New Power 30, 2022 LinkedIn Top Voices in the Green Economy, and Crain’s 40 Under 40 lists. Dr. Cooper has also been recognized as a Scholar at Google for Entrepreneurs, a 2021 Emerson Collective Dial Fellow, and one of the 100 most intriguing entrepreneurs in 2021 as determined by Goldman Sachs. Dr. Cooper has published in high-impact, peer-reviewed international journals and holds a U.S. patent. He holds a PhD in neuroscience from Northwestern University, a certificate in management from the Kellogg School of Management, and a BS & BA in mathematics and chemistry from Indiana University.

e.019 follows the journey of Dr. Jim Sullivan––the co-founder and CEO of Vanqua Bio. Tune in to hear John Flavin and the Chicago Biomedical Consortium Entrepreneurial Fellows engage with Jim, aiming to learn more about the life sciences industry and the different means of entry (to various opportunities). Previously, Jim was the Vice President of Research at Abbvie where he was responsible for the company’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis. Jim has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms. Jim is an adjunct faculty member at Northwestern University and serves on the board of several companies and foundations including Regis Technologies, Genomics Medicine Ireland, Genuity Science, MATTER Healthcare Incubator, Chicago Biotechnology Accelerator and the Pistoia Alliance. He earned his bachelor’s degree and Ph.D. in biochemistry from Trinity College Dublin and conducted post-doctoral research in neurobiology at Northwestern University.

Go Big or Go Home: John Flavin talks Texas-style life sciences with innovation leaders Tom Luby and Sarah Hein from Texas Medical Center Innovation in e.018. New developments in Houston are setting the stage for accelerated growth in the start-up ecosystem. Investments being made by member institutions such as MD Anderson, Baylor, Texas A&M, Texas, Rice and others into innovation platforms and top-tier applied researchers means: more commercialization of new drugs and devices is on the horizon. TMC is building the infrastructure and community to create the conditions to allow for rapid scaling of the ecosystem.Tom Luby Ph.D. is the Director of Texas Medical Center (TMC) Innovation.  In this role, he oversees all of the innovation efforts of TMC focused on research, education, and commercialization of novel healthcare solutions.  Prior to this, he was the head of JLABS @ TMC in Houston, Texas. Tom started at Johnson & Johnson Innovation as a New Ventures Lead at the Johnson & Johnson Innovation Center in Boston. In that role, he was instrumental in fostering many deals for the Boston office, which included the expansion of JLABS to JLABS @ Toronto.  Prior to J&J, Tom spent 14 years in various R&D and business development positions, most recently as Sr. Director, Research Ventures at Shire. Nine of those years were spent working in R&D and operational roles across three start-up biotech companies in the Boston area. Tom received a Bachelor of Science in Biology from State University of New York, and a Ph.D. in Immunology from the Sackler School of Biomedical Sciences at Tufts University.Sarah Hein, PhD, is an Entrepreneur in Residence for the Texas Medical Center’s Cancer Therapeutics Accelerator. Previously, Sarah was cofounder and VP of Operations at Courier Therapeutics, where she helped develop a novel immune-targeted cancer immunotherapy. She was also Director of Research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her PhD from Baylor College of Medicine.Sarah earned her Bachelor’s and Master’s of Science from the University of Wyoming.

Following the voices of Michelle Hoffman, Azurii Collier, John Conrad and John Flavin, e.017 means to reach a community-based perspective, focusing on the factors that contribute to and resist change/growth in emerging life science ecosystems, especially Chicago. Azurii Collier is the Director of Enterprise Innovation at AbbVie and the National President-Elect of Women in Bio - an organization of professionals committed to promoting careers, leadership, and entrepreneurship for all women in the life sciences. Her background in Cognitive Neuroscience has been a driving force in leading transformations towards knowledge-based ecosystems. Michelle Hoffman is the Executive Director of The Chicago Biomedical Consortium (CBC)- and organization built to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois Chicago and others to accelerate discovery that will transform biomedical research and improve the health of humankind. She has particular expertise in healthcare analysis, biotech industry and market analysis. Her work with both large and small, private and public companies as contributed to the impact of her industry knowledge.John Conrad is the President & CEO at Illinois Biotechnology Innovation Organization (iBIO)-an organization dedicated to promoting, connecting and engaging the life sciences community to drive discovery, transform lives through groundbreaking research and grow the Illinois economy. John works alongside policymakers to tackle issues that affect the industry; his focus has been around establishing the Midwest as a viable place to grow a life science company.

e.016 meets Dr. Mandell - a scientist, entrepreneur, and leading expert in synthetic biology, protein engineering, artificial intelligence, and biological and medical informatics. Together with Dr. George Church, he leveraged Genomically Recoded Organisms (GROs) to produce the first proteins with stability and function dependent on non-standard amino acids. Last November Grobio closed a $25 million Series A financing led by  Leaps by Bayer and Redmile, a total investment to date of $31.2 million, to help fund the company’s scale-up of bioprocess manufacturing, preclinical validation studies and IND enabling studies.Dr. Mandell completed his research fellowship in genetics at Harvard Medical School where he was Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation. He received his PhD from the University of California, San Francisco, his MSc at University of Edinburgh, and his undergraduate degree in Symbolic Systems from Stanford University.

e.015 thinks Sree Kant is pretty phenomenal. Sree is an experienced biotech executive, and company builder. Over a 20-year career in life sciences and healthcare, he has worked across investing, operational, advisory, and entrepreneurial roles and functions. He is passionate about translating cutting edge science into therapies that significantly change health outcomes for patients.Before founding BAKX, Sree headed the Investments and Partnerships function at Life Biosciences, where he built platform focused companies in the areas of age-related diseases. He also took on operational roles in the portfolio companies driving the corporate development agenda. Prior to Life bio, Sree led early partnering strategy for Pfizer, driving strategic partnerships across different therapeutic areas/technologies and geographies. He also built Pfizer’s early target partnering vehicle and drove academic partnerships and spinouts to advance novel target platforms.Sree was also Principal at the Boston Consulting Group advising large pharma, biotech, and medical device companies in areas of Corporate development, R&D strategy, M&A, etc.  Sree started his career with Ranbaxy labs in New Delhi and London, and also was a founding member of India’s first preventative, managed health company.Sree has an MBA from the Indian Institute of Management, and an MPH from the Harvard School of Public Health.

Dr. Lishan Aklog's journey to entrepreneurial and professional success was not an easy road. As a teenager Dr. Aklog fled political violence in Ethiopia, which led him to become especially active in philanthropic organizations later in life. Dr. Aklog is a member of the NY Executive Committee, the Africa Advisory Committee, and the Human Rights Watch serving on its Board of Directors. In addition, he is Board Chairman of the Boston ECG Project Charitable Foundation Inc., a non-profit corporation whose purpose is to save the lives of children and adolescents by preventing sudden cardiac death and identifying occult underlying cardiac abnormalities and conditions. Previously, Dr. Aklog served on Barack Obama’s National Finance Committee in 2008.Dr. Aklog has been a heart surgeon for more than 20 years and received his degree from Harvard University, graduating Phi Beta Kappa and magna cum laude in Physics, and his M.D. degree, cum laude, from Harvard Medical School. He completed his surgical training at Harvard’s Brigham and Women’s Hospital and Boston Children’s Hospital, Harefield Hospital, London and L’Hôpital Broussais, Paris. He is also a prolific entrepreneur and innovator having started many impactful companies including PAVmed and Lucid Diagnostics that he took public on NASDAQ.PAVmed Inc. is a multi-product medical device medical technology company operating in the medical device, diagnostics, and digital health sectors. PAVmed in 2014 and it became public on Nasdaq in 2016.Lucid Diagnostics, a subsidiary of PAVmed Inc., is a commercial-stage, cancer prevention medical diagnostics company focused on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.